Data Showed AMRIX is Superior to Placebo, Similar Efficacy to Immediate Release Formulation Taken Three Times a Day, and Less Daytime Drowsiness
FRAZER, Pa., Feb. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced the pooled analysis of two pivotal randomized, placebo-controlled clinical trials showing that AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), a new once-daily extended-release skeletal muscle relaxant, was superior to placebo. AMRIX had similar efficacy to cyclobenzaprine immediate-release (CIR) taken three times a day in alleviating acute muscle spasm associated with lower back and neck pain. In addition, less daytime drowsiness was observed with AMRIX compared to CIR, although such a comparison was not pre-specified in the statistical analysis plan. These results were presented today at the 24th Annual Meeting of the American Academy of Pain Medicine in Orlando, FL.
"Typically, muscle relaxants are taken multiple times a day, which can make it difficult for some of my patients with acute muscle spasm associated with lower back and neck pain to adhere to their treatment regimen," said Arnold J. Weil, MD, of Non-Surgical Orthopaedics in Atlanta, GA, and the lead investigator in these studies. "With data supporting AMRIX as an effective once-daily treatment, health care professionals now have an easy-to-administer treatment option to offer their patients who are suffering from acute muscle spasm."
The data, which were the basis for the U.S. Food and Drug
Administration approval of AMRIX, were pooled from two identical 14-day
randomized, double-blind, placebo-controlled, multicenter studies,
evaluating a total of 504 adults across four study arms (AMRIX 15 mg, AMRIX
30 mg, placebo, and CIR 10 mg three times daily). These participants had
moderate-to-severe muscle spasm of cervical or lumbar origin associated
with local pain, tenderness, limitation of motion, and restrictions of
|SOURCE Cephalon, Inc.|
Copyright©2008 PR Newswire.
All rights reserved